RPG Life Sciences Limited RPGLIFE NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.rpglifesciences.com

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

Market & Price

Market Cap

₹3,679.43 Cr

Current Price

₹2,224.70

High / Low (52W)

₹2,657.80 / ₹1,744.00

Beta

-0.20

Valuation

Stock P/E

31.95

Industry PE

37.60

Forward P/E

77.84

PEG Ratio

Book Value

₹366.04

Price to Book

6.08

P/S

5.20

EV/EBITDA

23.28

Dividend Yield

0.90%

Profitability & Returns

ROCE

24.52%

ROE

20.28%

ROA

10.82%

Profit Margin

16.28%

Op Margin

15.31%

EPS (Latest Qtr)

₹18.08

EPS (TTM)

₹69.63

Balance Sheet & Liquidity

Debt/Equity

3.30

Quick Ratio

2.44

Current Ratio

3.48

Debt

₹20.00 Cr

Total Assets

₹793.16 Cr

Current Assets

₹559.48 Cr

Working Capital

₹398.91 Cr

Ownership

Promoter Holding

75.30%

Chg in Prom Hold

FII / Inst Holding

5.54%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹3,423.66 Cr

Total Revenue (TTM)

₹707.52 Cr

EBITDA

₹147.09 Cr

Free Cash Flow

₹-15.23 Cr

Operating Cash Flow

₹56.50 Cr

Shares Outstanding

₹1.65 Cr

Gross Margin

64.37%

Payout Ratio

28.72%

Growth (CAGR)

Revenue 5Y

11.60%

Profit 5Y

19.41%

Revenue (YoY)

23.60%

Earnings (YoY)

-74.50%

PROS

Strong return on equity of 20.3%.
Healthy ROCE of 24.5%.
Compounding revenue at 11.6% over 5 years.
Profit CAGR of 19.4% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RPGLIFE RPG Life Sciences Limited NSEPHARMA	2,224.70	31.95	₹3,679.43 Cr	0.90%	24.52%	20.28%	11.60%	19.41%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	-	172.71 Cr	143.09 Cr	168.92 Cr	180.03 Cr	176.89 Cr
Cost of Revenue	-	56.11 Cr	48.72 Cr	60.02 Cr	64.90 Cr	60.59 Cr
Gross Profit	-	116.60 Cr	94.37 Cr	108.90 Cr	115.13 Cr	116.30 Cr
Operating Expenses	-	72.90 Cr	74.25 Cr	78.57 Cr	80.75 Cr	89.21 Cr
Operating Income	-	43.70 Cr	20.12 Cr	30.33 Cr	34.38 Cr	27.09 Cr
EBITDA	-	52.47 Cr	140.45 Cr	40.70 Cr	34.75 Cr	46.33 Cr
Interest Expense	-	12.00 L	18.00 L	13.00 L	25.00 L	39.00 L
Pretax Income	-	46.89 Cr	134.90 Cr	35.43 Cr	29.12 Cr	40.20 Cr
Tax Provision	-	11.96 Cr	17.55 Cr	9.14 Cr	6.99 Cr	10.30 Cr
Net Income	-	34.93 Cr	117.35 Cr	26.29 Cr	22.13 Cr	29.90 Cr
Diluted EPS	-	21.12	70.96	15.90	13.38	18.08

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	509.08 Cr	577.48 Cr	653.43 Cr	707.52 Cr
Cost of Revenue	-	178.23 Cr	194.20 Cr	214.01 Cr	252.09 Cr
Gross Profit	-	330.85 Cr	383.28 Cr	439.42 Cr	455.43 Cr
Operating Expenses	-	241.97 Cr	271.21 Cr	301.20 Cr	329.82 Cr
Operating Income	-	88.88 Cr	112.07 Cr	138.22 Cr	125.61 Cr
EBITDA	-	107.49 Cr	135.36 Cr	254.93 Cr	176.57 Cr
Interest Expense	-	31.00 L	45.00 L	62.00 L	89.00 L
Pretax Income	-	91.68 Cr	117.84 Cr	232.88 Cr	154.20 Cr
Tax Provision	-	24.04 Cr	30.18 Cr	49.64 Cr	39.03 Cr
Net Income	-	67.64 Cr	87.66 Cr	183.24 Cr	115.17 Cr
Diluted EPS	-	40.90	53.01	110.80	69.64

Compounded Sales Growth

5 Years:	11.60%
1 Year:	23.60%

Compounded Profit Growth

5 Years:	19.41%
1 Year:	-74.50%

Stock Price Performance

1 Year:	+4.08%
6 Months:	-1.02%
3 Months:	+16.56%
1 Month:	+9.56%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	419.35 Cr	512.87 Cr	657.81 Cr	793.16 Cr
Current Assets	-	264.05 Cr	298.09 Cr	465.25 Cr	559.48 Cr
Cash & Equivalents	-	24.82 Cr	19.72 Cr	28.70 Cr	150.46 Cr
Inventory	-	95.05 Cr	101.00 Cr	92.98 Cr	123.84 Cr
Receivables	-	37.43 Cr	49.13 Cr	86.76 Cr	116.68 Cr
Total Liabilities	-	111.75 Cr	138.02 Cr	127.28 Cr	187.81 Cr
Current Liabilities	-	102.78 Cr	130.96 Cr	119.83 Cr	160.57 Cr
Long Term Debt	1.00 L	0	-	-	13.33 Cr
Total Debt	94.00 L	1.00 L	0	-	20.00 Cr
Total Equity	-	307.60 Cr	374.85 Cr	530.53 Cr	605.35 Cr
Shares Outstanding	-	1.65 Cr	1.65 Cr	1.65 Cr	1.65 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	90.82 Cr	94.36 Cr	77.86 Cr	56.50 Cr
Investing Cash Flow	-	-105.81 Cr	-79.15 Cr	-41.80 Cr	85.84 Cr
Financing Cash Flow	-	-17.12 Cr	-20.31 Cr	-27.08 Cr	-20.58 Cr
Capital Expenditure	-	-32.73 Cr	-69.23 Cr	-36.03 Cr	-65.36 Cr
Free Cash Flow	-	58.09 Cr	25.13 Cr	41.83 Cr	-8.86 Cr
Net Change in Cash	-	-32.11 Cr	-5.10 Cr	8.98 Cr	121.76 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	65.0%	66.4%	67.2%	64.4%
Operating Margin %	-	17.5%	19.4%	21.2%	17.8%
Net Margin %	-	13.3%	15.2%	28.0%	16.3%
ROE %	-	22.0%	23.4%	34.5%	19.0%
ROCE %	-	28.1%	29.3%	25.7%	19.9%

Shareholding Pattern

Insiders

75.30%

Institutions

5.54%

Public Float

22.45%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RPGLIFE

No recent headlines available.

RPGLIFE · Healthcare